PRINCETON, N.J., June 30, 2014 /PRNewswire/ -- Agile Therapeutics,
Inc., (NASDAQ: AGRX), a women's health specialty pharmaceutical
company focused on the development and commercialization of new
prescription contraceptive products, today announced it has been
added to the Russell Microcap Index. The company joined the index
at the close of the market on Friday, June
27, 2014 when Russell Investments reconstituted its U.S. and
global equity indexes.
Membership in the Russell Microcap Index, which remains in place
for one year, means automatic inclusion in the appropriate growth
and value style indexes. Russell determines membership for its
equity indexes primarily by objective, market-capitalization
rankings and style attributes. Russell indexes are widely
used by investment managers and
institutional investors for index funds and as benchmarks
for active investment strategies.
Annual reconstitution of Russell Indexes captures the 4,000
largest U.S. stocks as of the end of May, ranking them by total
market capitalization to create the Russell 3000® Index and Russell
Microcap Index. Russell Investments comprehensive set of U.S.
and global equity indexes final listing is available on
www.russell.com/indexes.
About Agile
Agile Therapeutics is a women's health specialty pharmaceutical
company focused on the development and commercialization of new
prescription contraceptive products. Our product candidates are
designed to provide women with contraceptive options that offer
greater convenience and facilitate compliance. Our lead product
candidate, Twirla™, also known as AG200-15, is a once-weekly
prescription contraceptive patch currently in Phase 3 clinical
development. Twirla is based on our proprietary transdermal patch
technology, called Skinfusion®, which is designed to provide
advantages over currently available patches and is intended to
optimize patch adherence and patient acceptability. For more
information, please visit www.agiletherapeutics.com.
SOURCE Agile Therapeutics